European Innovation Council

Immunethep is a biotechnology company focused on developing bacterial immunotherapies for immune system related diseases. It originated as a spin-off from the University of Porto, using proprietary technology to counter bacteria that suppress the host immune response. The company targets a shared virulence mechanism used by diverse bacteria responsible for life-threatening infections, aiming to create broad-spectrum immunotherapies and innovative neonatal vaccines to protect newborns from bacterial infections. Through its pipeline, Immunethep seeks to enable patients to mount effective immunity and reduce the burden of multi-bacterial diseases with advanced therapeutic strategies.

Immunethep is a biotechnology company focused on developing bacterial immunotherapies for immune system related diseases. It originated as a spin-off from the University of Porto, using proprietary technology to counter bacteria that suppress the host immune response. The company targets a shared virulence mechanism used by diverse bacteria responsible for life-threatening infections, aiming to create broad-spectrum immunotherapies and innovative neonatal vaccines to protect newborns from bacterial infections. Through its pipeline, Immunethep seeks to enable patients to mount effective immunity and reduce the burden of multi-bacterial diseases with advanced therapeutic strategies.

C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

Founded in 2015 by Jaime Campos, Sara Silva, and João Pedro Ribeiro, PeekMed specializes in developing a 3D pre-operative planning system for orthopedic surgery. Its software enables surgeons to plan various procedures, such as total joint replacements and fracture reductions, aiming to improve patient outcomes while reducing costs.

Criam is a Portuguese biotechnology company based in Braga that develops portable diagnostic technology for blood typing and infectious disease detection. Its stand-alone platform does not require electricity or laboratory infrastructure, enabling rapid testing at the point of care. A single reader can perform multiple tests using cartridges and computer vision algorithms to detect a broad range of diseases, including HIV, with real-time data to support clinical decisions. The system leverages lab-on-a-chip concepts and biomarker detection algorithms to deliver fast, user-friendly, and cost-effective diagnostics in diverse settings, including remote environments and emergency care.

C2C NewCap, founded in 2014 by Rui Silva and Andre Mao de Ferro, is a Lisbon-based manufacturer specializing in the production of supercapacitors designed for efficient electrical energy storage. The company focuses on developing next-generation devices that utilize proprietary electrodes and an aqueous electrolyte, which contribute to a low environmental impact. C2C NewCap aims to provide clients with energy storage solutions that not only enhance operational efficiency but also reduce overall environmental and operational costs.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.